Shield Therapeutics plc (LON:STX – Get Free Report) was down 4.9% during trading on Thursday . The stock traded as low as GBX 3.17 ($0.04) and last traded at GBX 3.22 ($0.04). Approximately 2,220,797 shares changed hands during trading, a decline of 17% from the average daily volume of 2,680,130 shares. The stock had previously closed at GBX 3.38 ($0.04).
Shield Therapeutics Price Performance
The company has a market cap of £24.79 million, a PE ratio of -79.25 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock’s 50-day moving average is GBX 2.70 and its 200 day moving average is GBX 3.32.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Insider Buying Explained: What Investors Need to Know
- 3 Must-Have ETFs Set to Dominate This Quarter
- The 3 Best Retail Stocks to Shop for in August
- Seeking Stability? These 3 Stocks Offer Strong Potential
- 10 Best Airline Stocks to Buy
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
